| Literature DB >> 35132376 |
Zhimin Yu1,2, Fangfang Zhang3, Chengkai Xu1, Yanggan Wang4,5.
Abstract
BACKGROUND: Antioxidants attracted long-standing attention as promising preventive agents worldwide. Previous observational studies have reported that circulating antioxidants are associated with reduced mortality; however, randomized clinical trials indicate neutral or harmful impacts. The association of long-term circulating antioxidant exposure with longevity is still unclear.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35132376 PMCID: PMC8817834 DOI: 10.1155/2022/4012603
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1A flow chart detailing data sources and study design for the MR study. Abbreviations: BMI: body mass index; GWAS: genome-wide association study; HDL-c: high-density lipoprotein cholesterol; IVW: inverse-variance weighted; LDL-c: low-density lipoprotein cholesterol; SNPs: single-nucleotide polymorphisms; T2DM: type 2 diabetes mellitus.
Description of data sources of the genetic instruments used for circulating antioxidants in the Mendelian randomization study.
| Antioxidant | Sample size | No. of SNPs | Unit | Ancestry |
| Variance (%)† | Overlap§ | PMID |
|---|---|---|---|---|---|---|---|---|
| Absolute circulating antioxidants | ||||||||
| Ascorbate | 15,087 | 10 |
| European | 5 | 1.87% | None | 33203707 |
| Lycopene | 441 | 5 |
| European | 5 | 30.1% | None | 26861389 |
| Selenium | 4,162 | 4 |
| Primarily European∗ | 5 | 5.9% | None | 25343990 |
| | 2,344 | 3 |
| European | 5 | 9.0% | None | 23134893 |
| Retinol | 5,006 | 2 |
| European | 5 | 2.3% | None | 21878437 |
| Circulating antioxidant metabolites | ||||||||
| Ascorbate | 2,063 | 14 | Log10-transformed metabolites | European | 1 | 18.6% | None | 24816252 |
| | 7,276 | 11 | Log10-transformed metabolites | European | 1 | 3.3% | None | 24816252 |
| | 5,822 | 13 | Log10-transformed metabolites | European | 1 | 15.0% | None | 24816252 |
| Retinol | 1,957 | 24 | Log10-transformed metabolites | European | 1 | 4.8% | None | 28263315 |
∗Study population contains both Europeans and African-American participants. †Explained variance for circulating antioxidant metabolites were as reported in GWASs or calculated using the formula of assuming no genetic interactions, where MAF denotes the minor allele frequency and β denotes the effect of SNPs on the antioxidant metabolites. §The estimated overlap of the longevity GWAS with the exposure GWASs. Abbreviation: SNPs: single-nucleotide polymorphisms.
Bioavailability and mode of action of the antioxidants included in this MR study.
| Antioxidants | Bioavailability | Mode of action |
|---|---|---|
|
| 4%-14% [ | Antioxidant activity, regulate detoxification enzymes, immune response and hormone metabolism, antibacterial and antiviral effects, anticancer property [ |
| Lycopene | 0.1%-1.5% [ | Maintain redox homeostasis, enhance autophagy, anti-inflammation, reduce lipid peroxidation and LDL-c, inhibit proliferation of neoplastic cells [ |
| Selenium | 55%-65% [ | Maintain redox homeostasis, maintain the physiological functions of brain, anti-inflammatory and antiviral properties, participate in thyroid hormone metabolism, cancer prevention [ |
| Vitamin A | 75%-100% [ | Maintain normal functions of visual system and reproduction, anti-inflammation, modulate immunity, promote cell differentiation, regulate cell growth, maintain epithelial integrity, antithrombosis, cancer prevention [ |
| Vitamin C | 49%-90% [ | Antioxidant function, increase endothelium-dependent vasodilatation, inhibit lipid peroxidation, increase the absorption of iron, participate in energy-yielding metabolism and collagen synthesis [ |
| Vitamin E | 50%-80% [ | Antioxidant function, anticancer effects, anti-inflammation, inhibit cell proliferation, antiangiogenesis, immune modulation, inhibit HMG-CoA reductase enzyme [ |
Abbreviations: LDL-c: low-density lipoprotein cholesterol; HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme A.
Figure 2Odds ratios for relationships between genetically predicted circulating antioxidants and longevity (n = 36,745). The ORs for absolute antioxidants represent the effect of per unit increase in ln-transformed selenium, -carotene, and retinol values, 1 mmol/l ascorbate and 1 mg/dl lycopene, on longevity. For antioxidant metabolites, ORs represent the effect of per 10-fold increase in the antioxidant metabolite's level on longevity. All estimates were calculated based on random-effect IVW method. The Pheterogeneity values derived from the Cochran's Q statistics were used to reflect heterogeneity between the SNP-specific estimates. Abbreviations: CI: confidence interval; IVW: inverse-variance weighted; OR: odds ratio; SNP: single nucleotide polymorphism.
Figure 3MR estimates for relationships between genetically predicted circulating antioxidants and lifespan years (n = 1,012,240). The effect estimates for absolute antioxidants represent the change in lifespan years per unit increase in ln-transformed selenium, -carotene, and retinol values, 1 mmol/l ascorbate and 1 mg/dl lycopene. For antioxidant metabolites, the estimates are expressed as change in lifespan years per 10-fold increase in antioxidant metabolite's level. All estimates were calculated based on random-effect IVW method. The Pheterogeneity values derived from Cochran's Q statistics were used to reflect heterogeneity between the SNP-specific estimates. Abbreviations: CI: confidence interval; IVW: inverse-variance weighted; MR: Mendelian randomization; SNP: single nucleotide polymorphism.
IVW findings and sensitivity analyses for genetically predicted per unit increase in circulating antioxidants and individual longevity outcome.
| Antioxidants | IVW/Wald ratio | Weighted median | MR-Egger | MR-PRESSO | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) |
|
| OR (95% CI) |
| OR (95% CI) |
| Intercept ( | No. of outliers | OR (95% CI) |
| |
|
| |||||||||||
| Ascorbate ( | 0.96 (0.74-1.24) | 0.758 | 0.160 | 1.17 (0.88-1.57) | 0.281 | 1.24 (0.87-1.79) | 0.272 | -0.024 (0.110) | 0 | 0.96 (0.74-1.24) | 0.766 |
| Lycopene ( | 1.00 (0.91-1.09) | 0.996 | 0.522 | 0.99 (0.88-1.11) | 0.805 | 0.90 (0.76-1.06) | 0.299 | 0.043 (0.081) | 0 | 1.00 (0.92-1.08) | 0.996 |
| Selenium (ln-transformed) | 0.92 (0.83-1.03) | 0.144 | 0.968 | 0.93 (0.82-1.05) | 0.229 | 0.98 (0.69-1.40) | 0.931 | -0.016 (0.285) | 0 | 0.92 (0.89-0.95) | 0.015 |
|
| 1.04 (0.87-1.26) | 0.653 | 0.549 | 1.04 (0.85-1.26) | 0.715 | 0.85 (0.42-1.68) | 0.716 | 0.028 (0.615) | NA | NA | NA |
| Retinol (ln-transformed) | 0.49 (0.18-1.34) | 0.163 | 0.266 | NA | NA | NA | NA | NA | NA | NA | NA |
|
| |||||||||||
|
| 1.02 (0.53-1.97) | 0.955 | 0.782 | 1.02 (0.42-2.50) | 0.960 | 0.66 (0.16-2.77) | 0.581 | 0.013 (0.430) | 0 | 1.02 (0.69-1.49) | 0.945 |
|
| 1.02 (0.69-1.49) | 0.936 | 0.189 | 1.09 (0.66-1.79) | 0.733 | 1.30 (0.58-2.90) | 0.537 | -0.011 (0.507) | 0 | 1.01 (0.69-1.49) | 0.938 |
| Retinol (log10 units) | 1.07 (1.02-1.13) | 0.008 | 0.360 | 1.07 (0.99-1.15) | 0.050 | 1.01 (0.87-1.18) | 0.877 | 0.012 (0.512) | 0 | 1.07 (1.02-1.13) | 0.015 |
| Ascorbate (log10 units) | 0.97 (0.80-1.17) | 0.731 | 0.025 | 0.80 (0.64-1.00) | 0.050 | 0.96 (0.66-1.40) | 0.838 | 7.04 | 1 | 0.86 (0.72-1.02) | 0.116 |
Abbreviations: CI: confidence interval; IVW: inverse-variance weighted; MR-PRESSO: MR pleiotropy residual sum and outlier; NA: not available; OR: odds ratio.
Figure 4MR results for absolute antioxidant exposure and factors that may determine life expectancy. Results are reported as beta coefficients and 95% CIs showing factor unit differences (in parentheses) per unit increase in ln-transformed -carotene and retinol values, 1 mmol/l ascorbate and 1 mg/dl lycopene. The random-effect IVW method was applied in the MR analysis. P value below 0.05 was highlighted.
Figure 5MR results for antioxidant metabolite exposure and factors that may determine life expectancy. Results are reported as beta coefficients and 95% CIs showing factor unit differences (in parentheses) per 10-fold increase in antioxidant metabolites' level. Random-effect IVW method was applied in the MR analysis.